Company news

Mosim signed a strategic partnership with Tigermed

2015/12/23 17:58:56Browsing Times:1273

Shanghai Mosim Co., Ltd. (hereinafter referred to as "Mosim") and Hangzhou Tigermed Consulting Co., Ltd (hereinafter referred to as "Tigermed") signed a "strategic cooperation agreement"on December 23, 2015. Both sides will carry out strategic cooperation in clinical drug development. 
Under the agreement, Mosim and Tigermed will collaborate on clinical trial design, PK/PD data analysis, PK/PD modeling and simulation, etc., providing domestic and foreign customers with the one-stop services of clinical drug development.

About Mosim
Mosim is the leading biopharmaceutical services company in China, offering clinical pharmacology, biostatistics, clinical data management and medical writing services. Since its foundation in 2015, Mosim has grown into a team of over 20 staff members. It is headquartered in Zhangjiang Pharma Valley, with branch offices in Nanjing and Beijing. Our clients include the top pharmaceutical and biotechnology companies, both in China and overseas.

About Tigermed
Hangzhou Tigermed Consulting Co., Ltd(stock symbol: 300347) is a leading Contract Research Organization (CRO) in China dedicated to provide professional full clinical trial services. Since inception in 2004, Tigermed has been committed to accelerating medical product development with costs efficiency and quality.
Headquartered in Hangzhou, Tigermed operates 33 subsidiaries, 53 offices across China and 10 overseas offices in Hong Kong, Taiwan, USA, Canada, Korea, Australia, Japan, Malaysia, Singapore and India with over 1800 full time staffs. Tigermed has set up international standard SOPs and serviced more than 300 local and global clients in the conduct of over 400 clinical trials. Tigermed is recognized as “The Innovative CRO” in China, owing to its involvement of the development of many innovative drugs.
For more information about Tigermed, please visit